Novo Nordisk's Pipeline Puzzle: One Candidate Fades as Another Finds Younger Patients

Novo Nordisk shares fall 5% on Ziltivekimab trial setback, while pediatric obesity data and oral Wegovy launch offer some support ahead of capital markets day.

The arithmetic at Novo Nordisk has grown unusually awkward. A flagship cardiovascular candidate is effectively unravelling in public, while the company's blockbuster weight-loss franchise keeps opening new doors — most recently to children as young as six. Investors, caught between those two trajectories, have spent the past week voting with their feet.

The stock, trading at €38.45, has shed nearly 5 percent in seven sessions and sits 13 percent below its January level. That leaves the shares roughly 30 percent adrift of their €54.86 52-week peak, with a relative strength index of 40 pointing to a name that is technically bruised but not yet washed out.

A cardiology setback with compounding consequences

The immediate source of discomfort traces back to Ziltivekimab, the once-promising cardiovascular asset that was meant to diversify Novo's reliance on its GLP-1 franchise. The ZEUS study missed its primary endpoint, and an independent data monitoring committee subsequently pulled the plug on two further heart-failure trials, citing a "low probability" of a divergent outcome. What remains is a single study in post-heart-attack patients, with results not expected until the first half of 2027.

That timeline leaves a conspicuous hole in the pipeline narrative. Citi, which reiterated its sell rating and DKK 265 price target on September 2, pointed to slowing new-prescription trends for Novo's key obesity drugs — the oral Wegovy formulation being the notable exception — based on weekly IQVIA tracker data.

The paediatric bright spot

Against that gloom, the STEP-Young study offered a genuine counterpoint. Weekly semaglutide in children aged six to under twelve delivered a greater BMI reduction than placebo, with 40.4 percent of treated children no longer classified as obese after 68 weeks and no new safety signals emerging. The data opens a potentially meaningful new patient population for the GLP-1 platform.

The oral story is also advancing. Wegovy's tablet version launched in Germany last Friday — the first EU market for the formulation — with additional countries slated to follow later this year. Since that launch, the shares have nonetheless slipped 3.7 percent, underscoring how difficult it has become for positive news to move the needle.

Analysts remain split

The sell-side has yet to converge on a view. Deutsche Bank has returned to a sell stance and recently reaffirmed it, while J.P. Morgan and Barclays both hold at neutral. The scepticism persists despite a beat on both earnings per share and revenue, powered by robust GLP-1 demand. The gross margin, however, contracted meaningfully under pricing pressure and higher production costs, prompting management to trim its full-year operating profit guidance.

The buyback machine, for its part, continues to run — with B-shares repurchased in the hundreds of millions of euros most recently — offering a floor of sorts beneath the share price even as the clinical narrative wobbles.

What the capital markets day must deliver

All of this converges on September 21, when Novo hosts its capital markets day. Management faces a pointed question: how does the company fill the Ziltivekimab gap while prescription trends soften and the pipeline beyond GLP-1 thins out?

The bull case rests on the paediatric data translating into regulatory uptake and the oral Wegovy expansion gathering momentum across Europe, diversifying revenue away from injectables. The bear case is that the Ziltivekimab retreat is not an isolated stumble but a pattern — and that if the remaining post-heart-attack study also disappoints, the growth narrative will rest on a narrower foundation than investors have been led to believe.

With the stock's elevated annualised volatility reflecting that uncertainty, the capital markets day now carries unusual weight. Until then, Novo Nordisk remains a name for investors comfortable watching a story resolve itself in real time — one trial result at a time.